

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 12:23:14 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 57 TO ITERATE

100.0% PROCESSED 57 ITERATIONS

29 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 688 TO 1592

PROJECTED ANSWERS: 257 TO 903

L2 29 SEA SSS SAM L1

=> => s l1 sss ful

FULL SEARCH INITIATED 12:28:23 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1068 TO ITERATE

100.0% PROCESSED 1068 ITERATIONS



485 ANSWERS

SEARCH TIME: 00.00.01

L3 485 SEA SSS FUL L1

=>

Uploading C:\Program Files\Stnexp\Queries\10507081 (sub).str



chain nodes :  
 7 8 10 11 14 15 18  
 ring nodes :  
 1 2 3 4 5 6  
 chain bonds :  
 3-7 7-11 10-11 10-18 14-15  
 ring bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6  
 exact/norm bonds :  
 3-7 7-11 10-11 10-18  
 exact bonds :  
 14-15  
 normalized bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6

G1: Cy, [\*1]

Match level :  
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom  
 11:Atom 14:CLASS 15:CLASS 18:CLASS  
 Generic attributes :  
 10:  
 Saturation : Unsaturated  
 Number of Carbon Atoms : less than 7  
 Number of Hetero Atoms : 2 or more

=&gt;

Uploading C:\Program Files\Stnexp\Queries\10507081.str



```

chain nodes :
13 15 22 36
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 23 24 25 26 27 28 29 30 31 32
ring/chain nodes :
17 18
chain bonds :
4-13 9-13 15-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 23-24 23-27
24-25 25-26 26-27 28-29 28-32 29-30 30-31 31-32
exact/norm bonds :
4-13 9-13 15-22 23-24 23-27 25-26 26-27 28-29 28-32 30-31 31-32
exact bonds :
24-25 29-30
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 : 23 : 28 :

```

G1:[\*1],[\*2]

G2:[\*3],[\*4]

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 15:CLASS 16:Atom 17:CLASS 18:CLASS 22:CLASS
23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom
32:Atom 36:CLASS 37:Atom

```

Type of Ring System : Monocyclic  
 11:  
 Saturation : Unsaturated  
 Number of Carbon Atoms : less than 7  
 Number of Hetero Atoms : 2 or more  
 Type of Ring System : Monocyclic

Element Count :  
 Node 10: Limited  
   C,C3  
   N,N2  
   O,O0  
   S,S0

Node 11: Limited  
   C,C4  
   N,N2  
   S,S0  
   O,O0

L4       STRUCTURE UPLOADED

=> d 14  
 L4 HAS NO ANSWERS  
 L4       STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s 14 sub=13 sss sam  
 SAMPLE SUBSET SEARCH INITIATED 12:32:10 FILE 'REGISTRY'  
 SAMPLE SUBSET SCREEN SEARCH COMPLETED -       29 TO ITERATE

100.0% PROCESSED       29 ITERATIONS       9 ANSWERS  
 SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):	ONLINE	**COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):	257 TO	903
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):	9 TO	360

L5       9 SEA SUB=L3 SSS SAM L4

=> => s 14 sub=13 sss ful  
 FULL SUBSET SEARCH INITIATED 12:34:09 FILE 'REGISTRY'  
 FULL SUBSET SCREEN SEARCH COMPLETED -       485 TO ITERATE

100.0% PROCESSED       485 ITERATIONS       97 ANSWERS  
 SEARCH TIME: 00.00.01

L6       97 SEA SUB=L3 SSS FUL L4

=> s 13 not 16  
 L7       388 L3 NOT L6

10/507,081

=> => s 17

L8 9 L7

=> d 18 1-9 bib,ab,hitstr

L8 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2007:410789 CAPLUS  
 TI New pyrimidine derivatives and their use in therapy as well as the use of  
 pyrimidine derivatives in the manufacture of a medicament for prevention  
 and/or treatment of Alzheimer's disease  
 IN Andersson, Lars; Arzel, Erwan; Berg, Stefan; Burrows, Jeremy; Hellberg,  
 Sven; Huerta, Fernando; Pedersen, Torben; Rein, Tobias; Rotticci, Didier;  
 Staaf, Karin; Turek, Dominika  
 PA Astrazeneca AB, Swed.  
 SO PCT Int. Appl., 244pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007040440	A1	20070412	WO 2006-SE1116	20061002
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI SE 2005-2174 A 20051003


AB The invention relates to use of compds. of formula I as a free base or a  
 pharmaceutically acceptable salt, solvate or solvate of salt thereof, a  
 process for their preparation and intermediates used therein, as pharmaceutical  
 ingredients for treatment of dementia, Alzheimer's Disease, Parkinson's  
 Disease, Frontotemporal dementia Parkinson's Type, Parkinson dementia  
 complex of Guam, HIV dementia, diseases with associated neurofibrillar tangle  
 pathologies and/or dementia pugilistica. Compds. of formula I wherein R1  
 is H, halo, CN, NO2, C1-3 (halo)alkyl, OH and derivs., SONH2 and derivs.,  
 etc.; R2 and R4 are independently H, halo, CN, NO2, C1-4 alkyl, C1-3  
 haloalkyl, OH and derivs. SONH2 and derivs., etc.; R1R2 taken together  
 with the atoms they are attached form (un)substituted 5- or 6-membered  
 heterocyclic ring; R3 and R5 are independently H, halo, CN, C1-3  
 (halo)alkyl, and OH and derivs.; R6 is CH2, C6 (halo)alkyl, C6 alkenyl, C6  
 alkynyl, and (un)substituted 6-membered heterocyclic ring; R7 is H,  
 (un)substituted C1-3 (halo)alkyl and CN; as free bases, pharmaceutically  
 acceptable salts, solvates, and solvates of salts thereof, are claimed.  
 Example compound II was prepared by stannylation of 1,2-dimethylimidazole with  
 trimethyltin chloride; the resulting 1,2-dimethyl-5-(trimethylstannyl)-1N-  
 imidazole underwent coupling with 2,4-dichloro-5-fluoropyrimidine to give  
 2-chloro-4-(1,2-dimethyl-1H-imidazol-5-yl)-5-fluoropyrimidine, which  
 underwent amination with 3-methoxy-5-trifluoromethylaniline to give compound  
 II. All the invention compds. were evaluated for their GSK3 $\beta$   
 inhibitory activity. From the assay, it was determined that compound II  
 exhibited a Ki value of 10 nM. These compds. may be useful in the  
 prevention and/or treatment of Alzheimer's disease. NOT to ANALYST:.  
 IT 933783-70-1P 933784-40-8P 933784-41-9P  
 933784-42-0P 933784-43-1P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

10/507,081

(drug candidate; preparation of pyrimidine derivs. and their use in therapy for prevention and/or treatment of Alzheimer's disease)


RN 933783-70-1 CAPLUS

CN 2-Pyrimidinamine, 4-(1,2-dimethyl-1H-imidazol-5-yl)-5-fluoro-N-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 933784-40-8 CAPLUS

CN 2-Pyrimidinamine, 4-(1,2-dimethyl-1H-imidazol-5-yl)-5-fluoro-N-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)



RN 933784-41-9 CAPLUS


CN 2-Pyrimidinamine, N-[3-chloro-4-(methylsulfonyl)phenyl]-4-(1,2-dimethyl-1H-imidazol-5-yl)-5-fluoro- (CA INDEX NAME)



RN 933784-42-0 CAPLUS


CN 2-Pyrimidinamine, N-[3-chloro-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-4-(1,2-dimethyl-1H-imidazol-5-yl)-5-fluoro- (CA INDEX NAME)

10/507,081



RN 933784-43-1 CAPLUS

CN 2-Pyrimidinamine, 4-(1,2-dimethyl-1H-imidazol-5-yl)-5-fluoro-N-[3-methyl-4-  
[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (CA INDEX NAME)





L8 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2007:150717 CAPLUS  
 DN 146:229372  
 TI Preparation of imidazolyl-pyrimidine compounds as CDK2 inhibitors  
 IN Andrews, David; Finlay, Maurice Raymond; Green, Clive; Jones, Clifford  
 PA Astrazeneca AB, Swed.; Astrazeneca Uk Limited  
 SO PCT Int. Appl., 159pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007015064	A1	20070208	WO 2006-GB2801	20060727
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	GB 2005-15743	A	20050730		
	GB 2005-20281	A	20051006		
	GB 2005-26015	A	20051222		
	GB 2006-8371	A	20060428		

OS MARPAT 146:229372

AB Title compds. I [R1 = Et, Pr, iso-Pr, etc.; R2 = Me, Et, iso-Pr, etc.; R3 = H or halo; R4 = H, ethynyl, halo, etc.; ring A = nitrogen-linked saturated ring which optionally contains an addnl. nitrogen, oxygen or sulfur atom; wherein 2 atoms of ring A, when ring A is a nitrogen-linked saturated ring, may optionally be connected by a one or two atom bridge.; and wherein if ring A contains an addnl. nitrogen atom that nitrogen may be optionally substituted by R7.; R5 = substituent on carbon and selected from halo, cyano, hydroxy, etc.; R7 = alkyl, alkanoyl, alkylsulfonyl, etc.; n = 0-2], pharmaceutically acceptable salts or in-vivo hydrolyzable ethers thereof were prepared For example, Pd(OAc)<sub>2</sub> catalyzed coupling reaction of 5-fluoro-4-(3-isopropyl-2-methyl-3H-imidazol-4-yl)pyrimidin-2-ylamine, e.g., prepared from (2E)-3-dimethylamino-1-(1-isopropyl-2-methyl-1H-imidazol-5-yl)prop-2-en-1-one in 2 steps, with (4-iodophenyl)-morpholin-4-yl-methanone afforded compound II [X = F]. In CDK2 (cyclin-dependent kinase 2) inhibition assays, compound II [X = H] exhibited the IC<sub>50</sub> value of 3 nM. Compds. I are claimed useful for the treatment of proliferative disorders.

IT 924641-86-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazolyl-pyrimidine compds. as CDK2 inhibitors for treatment of proliferative disorders)

RN 924641-86-1 CAPLUS

CN Methanone, [4-[[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-2-(methylsulfonyl)phenyl](4-methyl-1-piperazinyl)-, hydrochloride (1:?) (CA INDEX NAME)

10/507,081




●x HCl


RE.CNT 4      THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2004:1016036 CAPLUS  
 DN 141:424210  
 TI Preparation of 2-anilino-4-(imidazol-5-yl)pyrimidine derivatives and their use as cdk (cdk2) kinase inhibitors  
 IN Thomas, Andrew Peter  
 PA Astrazeneca AB, Swed.; Astrazeneca UK Limited  
 SO PCT Int. Appl., 48 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004101549	A1	20041125	WO 2004-GB2025	20040512
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1631566	A1	20060308	EP 2004-732343	20040512
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	JP 2006528962	T	20061228	JP 2006-530486	20040512
	US 2007037839	A1	20070215	US 2005-556561	20051114
PRAI	GB 2003-11276	A	20030516		
	WO 2004-GB2025	W	20040512		
OS	MARPAT 141:424210				
AB	Title compds. I [R1 = halo, NO2, CN, OH, NH2, carboxy, etc.; p = 0-4; R2 = sulfamoyl, etc.; q = 0-2; R3 = halo, NO2, CN, OH, CF3, etc.; n = 0-2; R4 = H, alk(en/yn)yl, cycloalkyl, etc.; R5 = H, halo, NO2, CN, etc.; R6 = H, alkyl, cycloalkyl, Ph, etc.] are prepared For instance, 2-Anilino-4-[1-isopropyl-2-(N-hydroxyiminomethyl)imidazol-5-yl]pyrimidine is prepared from the corresponding aldehyde and hydroxylamine. Selected compds. of the invention exhibit IC50 in the range of 1 mM to 1 nM for CDK2 kinase. I are useful for producing a cell cycle inhibitory (anti cell proliferation) effect.				
IT	796857-69-7P, 4-(2-Formyl-1-isopropylimidazol-5-yl)-2-[4-[N-(2-methoxyethyl)sulfamoyl]anilino]pyrimidine RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of 2-anilino-4-(imidazol-5-yl)pyrimidine derivs. and their use as cdk (cdk2) kinase inhibitors)				
RN	796857-69-7	CAPLUS			
CN	Benzenesulfonamide, 4-[[4-[2-formyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)				



IT 796857-68-6P, 4-[1-Isopropyl-2-(N-hydroxyiminomethyl)imidazol-5-yl]-2-[4-[N-(2-methoxyethyl)sulfamoyl]anilino]pyrimidine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of 2-anilino-4-(imidazol-5-yl)pyrimidine derivs. and their use as cdk (cdk2) kinase inhibitors)  
 RN 796857-68-6 CAPLUS  
 CN Benzenesulfonamide, 4-[[4-[2-[(hydroxyimino)methyl]-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-propyl- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:737755 CAPLUS  
 DN 139:261318  
 TI Preparation of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidines with CDK  
 inhibitory activity  
 IN Newcombe, Nicholas John; Thomas, Andrew Peter  
 PA Astrazeneca AB, Swed.; Astrazeneca UK Limited  
 SO PCT Int. Appl., 90 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

*Apple*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003076436	A1	20030918	WO 2003-GB983	20030306
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2478701	A1	20030918	CA 2003-2478701	20030306
	AU 2003214394	A1	20030922	AU 2003-214394	20030306
	JP 3569524	B1	20040922	JP 2003-574653	20030306
	JP 2005519135	T	20050630		
	BR 2003008212	A	20041221	BR 2003-8212	20030306
	EP 1487823	A1	20041222	EP 2003-709965	20030306
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2005131000	A1	20050616	US 2003-507081	20030306
	CN 1649863	A	20050803	CN 2003-810005	20030306
	JP 2004256550	A	20040916	JP 2004-129350	20040426
	IN 2004DN02489	A	20070406	IN 2004-DN2489	20040826
	ZA 2004006937	A	20060222	ZA 2004-6937	20040831
	NO 2004003851	A	20040914	NO 2004-3851	20040914
PRAI	GB 2002-5693	A	20020309		
	JP 2003-574653	A3	20030306		
	WO 2003-GB983	W	20030306		

OS MARPAT 139:261318

AB The title compds. [I; R1 = (un)substituted alkyl, alkylamino, heteroarylalkylamino, etc.; R2 = halo, CN, alkoxy, etc.; R3 = H, halo, CN; R4 = Me, Et, iso-Pr, etc.; R5 = H; Me, alkenyl, etc.; p = 0-2], use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man, were prepared and formulated. Thus, treating 2-anilino-4-(1-ethyl-2-methylimidazol-5-yl)pyrimidine (preparation given) with ClSO<sub>3</sub>H in SOCl<sub>2</sub> followed by reacting the resulting intermediate with 2-ethoxyethylamine and diethylmethylamine in MeOH afforded 47% I [R1 = 2-ethoxyethylamino; p = 0; R3 = H; R4 = Et; R5 = Me]. In general activity possessed by compds. I may be demonstrated at IC<sub>50</sub> values in the range 250 µM to 1 nM in the in vitro assay.


IT 602306-01-4P 602306-07-0P 602306-29-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidines with CDK

inhibitory activity)


RN 602306-01-4 CAPLUS

CN Glycine, N-[[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 602306-07-0 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)



RN 602306-29-6 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



IT 602305-61-3P 602305-62-4P 602305-63-5P  
 602305-64-6P 602305-65-7P 602305-66-8P  
 602305-67-9P 602305-68-0P 602305-69-1P  
 602305-70-4P 602305-71-5P 602305-72-6P  
 602305-73-7P 602305-74-8P 602305-75-9P  
 602305-76-0P 602305-77-1P 602305-78-2P  
 602305-79-3P 602305-80-6P 602305-81-7P  
 602305-82-8P 602305-83-9P 602305-84-0P  
 602305-85-1P 602305-86-2P 602305-87-3P  
 602305-88-4P 602305-89-5P 602305-90-8P  
 602305-91-9P 602305-92-0P 602305-93-1P  
 602305-94-2P 602305-95-3P 602305-96-4P  
 602305-97-5P 602305-98-6P 602305-99-7P  
 602306-00-3P 602306-02-5P 602306-03-6P  
 602306-04-7P 602306-05-8P 602306-06-9P  
 602306-08-1P 602306-09-2P 602306-10-5P  
 602306-11-6P 602306-12-7P 602306-13-8P


602306-14-9P 602306-15-0P 602306-16-1P  
 602306-17-2P 602306-18-3P 602306-19-4P  
 602306-20-7P 602306-21-8P 602306-22-9P  
 602306-23-0P 602306-24-1P 602306-25-2P  
 602306-26-3P 602306-27-4P 602306-28-5P  
 602306-30-9P 602306-32-1P 602306-33-2P  
 602306-35-4P 602306-36-5P 602306-37-6P  
 602306-38-7P 602306-39-8P 602306-40-1P  
 602306-41-2P 602306-42-3P 602306-43-4P  
 602306-44-5P 602306-45-6P 602306-46-7P  
 602306-47-8P 602306-48-9P 602306-49-0P  
 602306-50-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidines with CDK  
 inhibitory activity)


RN 602305-61-3 CAPLUS

CN Benzenesulfonamide, N-(2-ethoxyethyl)-4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 602305-62-4 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 602305-63-5 CAPLUS


CN Benzenesulfonamide, N-(1,1-dimethyl-2-propynyl)-4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 602305-64-6 CAPLUS


CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-

pyrimidinyl]amino]-N-[[6-(trifluoromethyl)-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)




RN 602305-65-7 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[2-(5-methyl-1H-1,2,4-triazol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 602305-66-8 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 602305-67-9 CAPLUS


CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[2-(3-pyridazinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 602305-68-0 CAPLUS


CN Benzenesulfonamide, N-[2-(3,5-dimethyl-1H-pyrazol-4-yl)ethyl]-4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)






RN 602305-69-1 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[3-(3-methyl-1H-pyrazol-4-yl)propyl]- (9CI) (CA INDEX NAME)




RN 602305-70-4 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[2-(4-pyridazinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 602305-71-5 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 602305-72-6 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[2-(1,2,5-thiadiazol-3-yloxy)ethyl]- (9CI) (CA INDEX NAME)




RN 602305-73-7 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[2-(3-isothiazolyloxy)ethyl]- (9CI) (CA INDEX NAME)




RN 602305-74-8 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[3-(3-isoxazolyloxy)propyl]- (9CI) (CA INDEX NAME)




RN 602305-75-9 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[2-(1-methylethoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 602305-76-0 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-propoxyethyl)- (9CI) (CA INDEX NAME)




RN 602305-77-1 CAPLUS

CN Benzenesulfonamide, N-[2-(1-methylethoxy)ethyl]-4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 602305-78-2 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(2-propoxyethyl)- (9CI) (CA INDEX NAME)




RN 602305-79-3 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[[4-[2-methyl-1-(2-methylpropyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 602305-80-6 CAPLUS

CN Benzenesulfonamide, N-(2-ethoxyethyl)-4-[[4-[2-methyl-1-(2-methylpropyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 602305-81-7 CAPLUS

CN Benzenesulfonamide, N-(2-ethoxyethyl)-4-[[4-(2-methyl-1-propyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 602305-82-8 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[[4-(2-methyl-1-propyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 602305-83-9 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 602305-84-0 CAPLUS

CN Benzenesulfonamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 602305-85-1 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 602305-86-2 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 602305-87-3 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




RN 602305-88-4 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 602305-89-5 CAPLUS

CN Benzenesulfonamide, N-(2-hydroxyethyl)-4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 602305-90-8 CAPLUS

CN Benzenesulfonamide, N-[3-(2-methoxyethoxy)propyl]-4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 602305-91-9 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-phenoxyethyl)- (9CI) (CA INDEX NAME)




RN 602305-92-0 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[2-(4-methoxyphenoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 602305-93-1 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[2-(2-methoxyphenoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 602305-94-2 CAPLUS

CN Benzenesulfonamide, N-[2-(ethenyloxy)ethyl]-4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 602305-95-3 CAPLUS


CN Benzenesulfonamide, N-[3-(1,1-dimethylethoxy)propyl]-4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 602305-96-4 CAPLUS

CN Benzenesulfonamide, N-[3-[2-(2-ethoxyethoxy)ethoxy]propyl]-4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CH<sub>2</sub>—OEt


RN 602305-97-5 CAPLUS

CN Benzenesulfonamide, N-[2-(dimethylamino)ethyl]-4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 602305-98-6 CAPLUS


CN Benzenesulfonamide, N-[2-(diethylamino)ethyl]-4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 602305-99-7 CAPLUS


CN Glycine, N-[[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)






RN 602306-00-3 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-[1-(phenylmethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)




RN 602306-02-5 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[[4-(1-propyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 602306-03-6 CAPLUS

CN Benzenesulfonamide, N-(2-ethoxyethyl)-4-[[4-(1-ethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 602306-04-7 CAPLUS

CN Benzenesulfonamide, N-(2-ethoxyethyl)-4-[[4-(1-propyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 602306-05-8 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-propyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 602306-06-9 CAPLUS

CN Benzenesulfonamide, N-cyclopropyl-4-[[4-(1-ethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 602306-08-1 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 602306-09-2 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(1,1-dimethylpropyl)- (9CI) (CA INDEX NAME)




RN 602306-10-5 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[2-(1H-pyrazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 602306-11-6 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 602306-12-7 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[2-hydroxy-1-(hydroxymethyl)ethyl]- (9CI) (CA INDEX NAME)




RN 602306-13-8 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-methoxy-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 602306-14-9 CAPLUS

CN Benzenesulfonamide, N-cyclopropyl-4-[[4-[1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 602306-15-0 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[[4-[1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 602306-16-1 CAPLUS

CN Benzenesulfonamide, 4-[[4-[1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 602306-17-2 CAPLUS

CN Benzenesulfonamide, N-methyl-4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 602306-18-3 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 602306-19-4 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-hydroxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 602306-20-7 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-3-fluoro-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 602306-21-8 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-3-fluoro- (9CI) (CA INDEX NAME)




RN 602306-22-9 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 602306-23-0 CAPLUS

CN Benzenesulfonamide, N-cyclopropyl-4-[[4-(1-propyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 602306-24-1 CAPLUS


CN Benzenesulfonamide, N-cyclopropyl-4-[[4-(2-methyl-1-propyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 602306-25-2 CAPLUS


CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[1,1-dimethyl-2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

10/507,081




RN 602306-26-3 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[1,1-dimethyl-2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 602306-27-4 CAPLUS

CN Benzenesulfonamide, N-(2-ethoxyethyl)-4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 602306-28-5 CAPLUS

CN 2-Pyrimidinamine, N-[4-[(3-methoxypropyl)sulfonyl]phenyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 602306-30-9 CAPLUS

CN 2-Pyrimidinamine, N-[4-[[3-(dimethylamino)propyl]sulfonyl]phenyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 602306-32-1 CAPLUS

CN 2-Pyrimidinamine, N-[4-(butylsulfonyl)phenyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 602306-33-2 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-[(3,3,3-trifluoropropyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 602306-35-4 CAPLUS


CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-methoxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 602306-36-5 CAPLUS


CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-[[tetrahydro-2-furanyl)methylsulfonyl]phenyl]- (9CI) (CA INDEX NAME)






RN 602306-37-6 CAPLUS

CN 2-Pyrimidinamine, N-[4-[(3-ethoxypropyl)sulfonyl]phenyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 602306-38-7 CAPLUS

CN Benzenesulfonamide, N-[2-(cyclopropylmethoxy)ethyl]-4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 602306-39-8 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[2-methoxy-1-(methoxymethyl)ethyl]- (9CI) (CA INDEX NAME)




RN 602306-40-1 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-ethoxy-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 602306-41-2 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(1-methylcyclopropyl)- (9CI) (CA INDEX NAME)




RN 602306-42-3 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(1-methyl-2-propoxyethyl)- (9CI) (CA INDEX NAME)




RN 602306-43-4 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[1,1-dimethyl-2-(methylthio)ethyl]- (9CI) (CA INDEX NAME)




RN 602306-44-5 CAPLUS

CN Benzenesulfonamide, 4-[[5-bromo-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 602306-45-6 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 602306-46-7 CAPLUS

CN Aziridine, 1-[[4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]sulfonyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 602306-47-8 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-[(phenylmethyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 602306-48-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-[[3-(4-morpholinyl)propyl]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 602306-49-0 CAPLUS

CN 2-Pyrimidinamine, 5-bromo-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 602306-50-3 CAPLUS

CN Glycine, N-[[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



IT 403791-37-7P 403792-07-4P 403792-46-1P  
602306-70-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidines with CDK inhibitory activity)

RN 403791-37-7 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-


10/507,081

pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 403792-07-4 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403792-46-1 CAPLUS

CN Benzenesulfonamide, 4-[[5-bromo-4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 602306-70-7 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[1,1-dimethyl-2-[[4-methylphenyl)sulfonyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:737754 CAPLUS  
 DN 139:261317  
 TI Preparation of 4-imidazolyl 2-sulfoanilino substituted pyrimidines with  
 CDK inhibitory activity  
 IN Newcombe, Nicholas John; Thomas, Andrew Peter  
 PA Astrazeneca AB, Swed.; Astrazeneca UK Limited  
 SO PCT Int. Appl., 68 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003076435	A1	20030918	WO 2003-GB957	20030306
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003214386	A1	20030922	AU 2003-214386	20030306
	EP 1485375	A1	20041215	EP 2003-709957	20030306
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005526071	T	20050902	JP 2003-574652	20030306
	US 2005256311	A1	20051117	US 2004-507162	20040909
PRAI	GB 2002-5688	A	20020309		
	WO 2003-GB957	W	20030306		

OS MARPAT 139:261317

AB The title compds. [I; R1 = halo, CN, alkyl, alkoxy; p = 0-2; R2 = NH2, R6, NHR6; R3 = H, halo, CN; R4 = cycloalkyl, CH2Ph, heterocyclyl, etc.; R5 = (un)substituted alkyl, alkenyl; R6 = alkyl, alkenyl, cycloalkyl, etc.], useful as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man, were prepared and formulated. Thus, treating 2-anilino-4-(1-cyclobutyl-2-methylimidazol-5-yl)pyrimidine (preparation given) with ClSO3H in SOCl2 followed by reaction of the resulting intermediate with cyclopropylmethylamine in MeOH afforded 63% I [p = 0; R2 = cyclopropylmethylamino; R3 = H; R4 = cyclobutyl; R5 = Me]. The compds. I demonstrated IC50 values in the range 250µM to 1 nM in the in vitro assay for testing CDK inhibitory activity.


IT 600699-04-5P 600699-05-6P 600699-06-7P  
 600699-07-8P 600699-08-9P 600699-11-4P  
 600699-15-8P 600699-16-9P 600699-17-0P  
 600699-18-1P 600699-19-2P 600699-20-5P  
 600699-21-6P 600699-22-7P 600699-23-8P  
 600699-24-9P 600699-25-0P 600699-26-1P  
 600699-27-2P 600699-28-3P 600699-29-4P  
 600699-30-7P 600699-31-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-imidazolyl 2-sulfoanilino substituted pyrimidines with CDK inhibitory activity)


RN 600699-04-5 CAPLUS

CN Benzenesulfonamide, 4-[[4-[1-(2-methoxy-1-methylethyl)-5-methyl-1H-imidazol-2-yl]-2-pyrimidinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 600699-05-6 CAPLUS

CN Benzenesulfonamide, 4-[[4-[1-(cyclopropylmethyl)-5-methyl-1H-imidazol-2-yl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 600699-06-7 CAPLUS

CN Benzenesulfonamide, 4-[[4-[1-(cyclopropylmethyl)-5-methyl-1H-imidazol-2-yl]-2-pyrimidinyl]amino]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 600699-07-8 CAPLUS

CN Benzenesulfonamide, N-cyclobutyl-4-[[4-[1-(cyclopropylmethyl)-5-methyl-1H-imidazol-2-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600699-08-9 CAPLUS

CN Benzenesulfonamide, N-(cyclopropylmethyl)-4-[[4-[1-(cyclopropylmethyl)-5-methyl-1H-imidazol-2-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 600699-11-4 CAPLUS


CN Benzenesulfonamide, 4-[[4-[1-(cyclopropylmethyl)-5-methyl-1H-imidazol-2-yl]-2-pyrimidinyl]amino]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 600699-15-8 CAPLUS


CN Benzenesulfonamide, 4-[[4-[1-(1-cyclopropylethyl)-5-methyl-1H-imidazol-2-yl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)






RN 600699-16-9 CAPLUS

CN Benzenesulfonamide, N-(2-ethoxyethyl)-4-[[4-[1-(2-methoxy-1-methylethyl)-5-methyl-1H-imidazol-2-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600699-17-0 CAPLUS

CN Benzenesulfonamide, 4-[[4-[1-(cyclopropylmethyl)-5-methyl-1H-imidazol-2-yl]-2-pyrimidinyl]amino]-N-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)




RN 600699-18-1 CAPLUS

CN Benzenesulfonamide, 4-[[4-[1-(1-cyclopropylethyl)-5-methyl-1H-imidazol-2-yl]-2-pyrimidinyl]amino]-N-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)




RN 600699-19-2 CAPLUS

CN Benzenesulfonamide, N-cyclopropyl-4-[[4-[1-(1-cyclopropylethyl)-5-methyl-1H-imidazol-2-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600699-20-5 CAPLUS

CN Benzenesulfonamide, 4-[[4-[1-(1-cyclopropylethyl)-5-methyl-1H-imidazol-2-yl]-2-pyrimidinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 600699-21-6 CAPLUS

CN Benzenesulfonamide, 4-[[4-[1-(1-cyclopropylethyl)-5-(methoxymethyl)-1H-imidazol-2-yl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)-, (9CI) (CA INDEX NAME)




RN 600699-22-7 CAPLUS

CN Benzenesulfonamide, 4-[[4-[1-(1-cyclopropylethyl)-5-(methoxymethyl)-1H-imidazol-2-yl]-2-pyrimidinyl]amino]-N-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)




RN 600699-23-8 CAPLUS

CN Benzenesulfonamide, N-(2-ethoxyethyl)-4-[[4-[5-ethyl-1-(2-methoxy-1-methylethyl)-1H-imidazol-2-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600699-24-9 CAPLUS

CN Benzenesulfonamide, 4-[[4-[5-ethyl-1-(2-methoxy-1-methylethyl)-1H-imidazol-2-yl]-2-pyrimidinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 600699-25-0 CAPLUS

CN Benzenesulfonamide, 4-[[4-[5-ethyl-1-(2-methoxy-1-methylethyl)-1H-imidazol-2-yl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 600699-26-1 CAPLUS

CN Benzenesulfonamide, N-cyclopropyl-4-[[4-[5-ethyl-1-(2-methoxy-1-methylethyl)-1H-imidazol-2-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600699-27-2 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[[4-[1-(2-methoxy-1-methylethyl)-5-propyl-1H-imidazol-2-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600699-28-3 CAPLUS

CN Benzenesulfonamide, N-(2-ethoxyethyl)-4-[[4-[1-(2-methoxy-1-methylethyl)-5-propyl-1H-imidazol-2-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600699-29-4 CAPLUS

CN Benzenesulfonamide, 4-[[4-[1-(cyclopropylmethyl)-5-ethyl-1H-imidazol-2-yl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 600699-30-7 CAPLUS

CN Benzenesulfonamide, N-methyl-4-[[4-[5-methyl-1-(phenylmethyl)-1H-imidazol-2-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 600699-31-8 CAPLUS

CN Benzenesulfonamide, 4-[[4-[1-(cyclopropylmethyl)-5-(2-methyl-1-propenyl)-1H-imidazol-2-yl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



IT 600700-01-4P 600700-02-5P 600700-03-6P


600700-04-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 4-imidazolyl 2-sulfoanilino substituted pyrimidines with CDK inhibitory activity)

RN 600700-01-4 CAPLUS


CN Benzenesulfonamide, 4-[[4-[1-(cyclopropylmethyl)-5-ethyl-1H-imidazol-2-yl]-2-pyrimidinyl]amino]-N-(1,1-dimethylethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 600700-02-5 CAPLUS


CN Benzenesulfonamide, 4-[[4-[1-(cyclopropylmethyl)-5-methyl-1H-imidazol-2-yl]-2-pyrimidinyl]amino]-N-(1,1-dimethylethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)

10/507,081




RN 600700-03-6 CAPLUS

CN Benzenesulfonamide, 4-[[4-[1-(cyclopropylmethyl)-5-(2-hydroxy-2-methylpropyl)-1H-imidazol-2-yl]-2-pyrimidinyl]amino]-N-(1,1-dimethylethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 600700-04-7 CAPLUS


CN Benzenesulfonamide, 4-[[4-[1-(cyclopropylmethyl)-5-(2-methyl-1-propenyl)-1H-imidazol-2-yl]-2-pyrimidinyl]amino]-N-(1,1-dimethylethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:737753 CAPLUS  
 DN 139:261316  
 TI Preparation of 4-imidazolyl substituted pyrimidines with CDK inhibitory activity  
 IN Newcombe, Nicholas John; Thomas, Andrew Peter  
 PA Astrazeneca AB, Swed.; Astrazeneca UK Limited  
 SO PCT Int. Appl., 90 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003076434	A1	20030918	WO 2003-GB935	20030306
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003208479	A1	20030922	AU 2003-208479	20030306
	EP 1490354	A1	20041229	EP 2003-706767	20030306
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005524672	T	20050818	JP 2003-574651	20030306
	US 2006074096	A1	20060406	US 2004-507169	20040909
PRAI	GB 2002-5695	A	20020309		
	GB 2002-17633	A	20020731		
	WO 2003-GB935	W	20030306		
OS	MARPAT 139:261316				
AB	The title compds. [I; R1 = halo, CN, alkyl, alkoxy; p = 0-2; R2 = H, alkyl, cycloalkyl, etc.; R3 = H, halo, CN; R4 = alkyl, alkoxyalkyl; R5 = Me, cycloalkyl, (un)substituted alkyl or alkenyl] and their pharmaceutically acceptable salts and in vivo hydrolysable esters, useful as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man, were prepared and formulated. Thus, treating 2-anilino-4-(1-methyl-2-isopropylimidazol-5-yl)pyrimidine (preparation given) with ClSO <sub>3</sub> H in SOCl <sub>2</sub> followed by reacting the resulting intermediate with cyclobutylamine afforded 65% I [p = 0; R2 = cyclobutyl; R3 = H; R4 = Me; R5 = iso-Pr]. In general, CDK inhibitory activity possessed by compds. I may be demonstrated at IC <sub>50</sub> values in the range 250µM to 1 nM in the in vitro assay.				
IT	600638-45-7P 600638-52-6P RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of 4-imidazolyl substituted pyrimidines with CDK inhibitory activity)				
RN	600638-45-7 CAPLUS				
CN	Benzenesulfonamide, 4-[[4-[2-(2-hydroxy-2-methylpropyl)-1-methyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)				



RN 600638-52-6 CAPLUS

CN Benzenesulfonamide, N-(2-ethoxyethyl)-4-[[4-[2-[(ethylthio)methyl]-1-propyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



IT 600637-71-6P 600637-72-7P 600637-73-8P  
 600637-74-9P 600637-75-0P 600637-76-1P  
 600637-77-2P 600637-78-3P 600637-79-4P  
 600637-80-7P 600637-81-8P 600637-82-9P  
 600637-83-0P 600637-84-1P 600637-85-2P  
 600637-86-3P 600637-94-3P 600637-95-4P  
 600637-96-5P 600637-97-6P 600637-98-7P  
 600637-99-8P 600638-00-4P 600638-01-5P  
 600638-02-6P 600638-03-7P 600638-04-8P  
 600638-05-9P 600638-06-0P 600638-07-1P  
 600638-08-2P 600638-09-3P 600638-10-6P  
 600638-11-7P 600638-12-8P 600638-13-9P  
 600638-18-4P 600638-19-5P 600638-20-8P  
 600638-21-9P 600638-22-0P 600638-23-1P  
 600638-24-2P 600638-25-3P 600638-26-4P  
 600638-27-5P 600638-28-6P 600638-29-7P  
 600638-30-0P 600638-31-1P 600638-32-2P  
 600638-33-3P 600638-34-4P 600638-35-5P  
 600638-36-6P 600638-37-7P 600638-38-8P  
 600638-39-9P 600638-40-2P 600638-41-3P  
 600638-42-4P 600638-43-5P 600638-44-6P  
 600638-46-8P 600638-47-9P 600638-48-0P  
 600638-49-1P 600638-50-4P 600638-51-5P  
 600638-53-7P 600638-54-8P 600638-55-9P  
 600638-56-0P 600639-56-3P 600639-57-4P  
 600639-58-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-imidazolyl substituted pyrimidines with CDK inhibitory activity)

RN 600637-71-6 CAPLUS


CN Benzenesulfonamide, N-cyclobutyl-4-[[4-[1-methyl-2-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)





RN 600637-72-7 CAPLUS


CN Benzenesulfonamide, 4-[[4-(1,2-diethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 600637-73-8 CAPLUS


CN Benzenesulfonamide, 4-[[4-(1,2-diethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 600637-74-9 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-diethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-ethoxyethyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 600637-75-0 CAPLUS  
 CN Benzenesulfonamide, 4-[[4-(1,2-diethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(3-methoxypropyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 600637-76-1 CAPLUS  
 CN Benzenesulfonamide, 4-[[4-[1-ethyl-2-(methoxymethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 600637-77-2 CAPLUS  
 CN Benzenesulfonamide, N-(2-ethoxyethyl)-4-[[4-[1-ethyl-2-(methoxymethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 600637-78-3 CAPLUS  
 CN Benzenesulfonamide, 4-[[4-[1-ethyl-2-(methoxymethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(3-methoxypropyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 600637-79-4 CAPLUS  
 CN Benzenesulfonamide, 4-[[4-[1-ethyl-2-(methoxymethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 600637-80-7 CAPLUS  
 CN Benzenesulfonamide, N-(cyclopropylmethyl)-4-[[4-[2-(methoxymethyl)-1-methyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 600637-81-8 CAPLUS


CN Benzenesulfonamide, N-cyclobutyl-4-[[4-[2-(methoxymethyl)-1-methyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 600637-82-9 CAPLUS

CN Benzenesulfonamide, N-(2-ethoxyethyl)-4-[[4-[2-(methoxymethyl)-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 600637-83-0 CAPLUS


CN Benzenesulfonamide, N-(2-ethoxyethyl)-4-[[4-[1-methyl-2-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 600637-84-1 CAPLUS


CN Benzenesulfonamide, 4-[[4-[1-methyl-2-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(2,2,2-trifluoroethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 600637-85-2 CAPLUS


CN Benzenesulfonamide, N-(1,1-dimethylethyl)-4-[[4-[1-methyl-2-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 600637-86-3 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-4-[[4-(2-ethyl-1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600637-94-3 CAPLUS

CN Benzenesulfonamide, N-cyclopropyl-4-[[4-[1-methyl-2-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 600637-95-4 CAPLUS


CN Benzenesulfonamide, N-(cyclopropylmethyl)-4-[[4-[2-(methoxymethyl)-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 600637-96-5 CAPLUS


CN Benzenesulfonamide, N-cyclopropyl-4-[[4-[2-(methoxymethyl)-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 600637-97-6 CAPLUS


CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[[4-[2-(methoxymethyl)-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, hydrochloride (9CI)  
(CA INDEX NAME)



●x HCl

RN 600637-98-7 CAPLUS


CN Benzenesulfonamide, N-cyclopropyl-4-[[4-[1-ethyl-2-(methoxymethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 600637-99-8 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-4-[[4-[1-ethyl-2-(methoxymethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 600638-00-4 CAPLUS


CN Benzenesulfonamide, N-cyclopropyl-4-[[4-(1,2-diethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-, hydrochloride (9CI) (CA INDEX NAME)

10/507,081




● x HCl

RN 600638-01-5 CAPLUS  
CN Benzenesulfonamide, 4-[[4-(1,2-diethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-2-propenyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 600638-02-6 CAPLUS  
CN Benzenesulfonamide, N-cyclopropyl-4-[[4-[2-(methoxymethyl)-1-methyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 600638-03-7 CAPLUS  
CN Benzenesulfonamide, 4-[[4-[2-(3,3-dimethylbutyl)-1-methyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)






RN 600638-04-8 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2-(3,3-dimethylbutyl)-1-methyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)




RN 600638-05-9 CAPLUS

CN Benzenesulfonamide, 4-[[4-(2-butyl-1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)




RN 600638-06-0 CAPLUS

CN Benzenesulfonamide, 4-[[4-(2-butyl-1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 600638-07-1 CAPLUS

CN Benzenesulfonamide, 4-[[4-[1,2-bis(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 600638-08-2 CAPLUS

CN Benzenesulfonamide, N-(2-ethoxyethyl)-4-[[4-(2-ethyl-1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600638-09-3 CAPLUS

CN Benzenesulfonamide, 4-[[4-[1,2-bis(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)




RN 600638-10-6 CAPLUS

CN Benzenesulfonamide, 4-[[4-[1-ethyl-2-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 600638-11-7 CAPLUS

CN Benzenesulfonamide, N-(2-ethoxyethyl)-4-[[4-[1-ethyl-2-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600638-12-8 CAPLUS

CN Benzenesulfonamide, 4-[[4-[1-ethyl-2-(methoxymethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 600638-13-9 CAPLUS

CN Benzenesulfonamide, N-(2-ethoxyethyl)-4-[[4-[2-(methoxymethyl)-1-methyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600638-18-4 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[[4-[2-(methoxymethyl)-1-propyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600638-19-5 CAPLUS

CN Benzenesulfonamide, N-(2-ethoxyethyl)-4-[[4-[2-(methoxymethyl)-1-propyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600638-20-8 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[[4-(1-methyl-2-propyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600638-21-9 CAPLUS

CN Benzenesulfonamide, N-(2-ethoxyethyl)-4-[[4-(1-methyl-2-propyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600638-22-0 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[[4-[2-(2-methoxyethyl)-1-methyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600638-23-1 CAPLUS

CN Benzenesulfonamide, N-(2-ethoxyethyl)-4-[[4-[2-(2-methoxyethyl)-1-methyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600638-24-2 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-propyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 600638-25-3 CAPLUS

CN Benzenesulfonamide, N-(2-ethoxyethyl)-4-[[4-(1-ethyl-2-propyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600638-26-4 CAPLUS

CN Benzenesulfonamide, 4-[[4-(2-butyl-1-ethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 600638-27-5 CAPLUS

CN Benzenesulfonamide, 4-[[4-(2-butyl-1-ethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)




RN 600638-28-6 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[[4-[1-(1-methylethyl)-2-propyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600638-29-7 CAPLUS

CN Benzenesulfonamide, N-(2-ethoxyethyl)-4-[[4-[1-(1-methylethyl)-2-propyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600638-30-0 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2-ethyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 600638-31-1 CAPLUS

CN Benzenesulfonamide, N-(2-ethoxyethyl)-4-[[4-[2-ethyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600638-32-2 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2-(ethoxymethyl)-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 600638-33-3 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[[4-[1-methyl-2-(2-methylpropyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600638-34-4 CAPLUS

CN Benzenesulfonamide, N-(2-ethoxyethyl)-4-[[4-[1-methyl-2-(2-methylpropyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600638-35-5 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dipropyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 600638-36-6 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dipropyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)




RN 600638-37-7 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2-(3,3-dimethylbutyl)-1-propyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 600638-38-8 CAPLUS


CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-propyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 600638-39-9 CAPLUS


CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-propyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)






RN 600638-40-2 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2-[(dimethylamino)methyl]-1-propyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 600638-41-3 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2-[(ethylamino)methyl]-1-propyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 600638-42-4 CAPLUS

CN Benzenesulfonamide, N-(2-ethoxyethyl)-4-[[4-[2-(methoxymethyl)-1-(2-methoxy-1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600638-43-5 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2-(2-ethyl-1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 600638-44-6 CAPLUS

CN Benzenesulfonamide, 4-[[4-(2-ethyl-1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 600638-46-8 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[[4-[1-(1-methylethyl)-2-(1-propenyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600638-47-9 CAPLUS

CN Benzenesulfonamide, 4-[[4-[1-ethyl-2-(2-methyl-1-propenyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 600638-48-0 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[[4-[1-methyl-2-(2-methyl-1-propenyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600638-49-1 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2-(3-butenyl)-1-propyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 600638-50-4 CAPLUS

CN Benzenesulfonamide, N-(2-ethoxyethyl)-4-[[4-[2-[(methylthio)methyl]-1-propyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600638-51-5 CAPLUS

CN Benzenesulfonamide, N-(2-ethoxyethyl)-4-[[4-[2-[[[1-methylethylthio)methyl]-1-propyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600638-53-7 CAPLUS

CN Benzenesulfonamide, N-(2-ethoxyethyl)-4-[[4-[2-[(ethylsulfinyl)methyl]-1-propyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600638-54-8 CAPLUS

CN Benzenesulfonamide, N-(2-ethoxyethyl)-4-[[4-[2-[(ethylsulfonyl)methyl]-1-propyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600638-55-9 CAPLUS

CN Benzenesulfonamide, N-(2-ethoxyethyl)-4-[[4-[2-[(1-methylethoxy)methyl]-1-propyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600638-56-0 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[[4-[1-methyl-2-(2-phenylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 600639-56-3 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-diethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)




RN 600639-57-4 CAPLUS

CN Benzenesulfonamide, N-cyclopropyl-4-[[4-(1,2-diethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 600639-58-5 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-diethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-2-propenyl- (9CI) (CA INDEX NAME)



IT 600639-31-4P 600639-33-6P 600639-38-1P

600639-39-2P 600639-40-5P 600639-41-6P


600639-44-9P 600639-50-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 4-imidazolyl substituted pyrimidines with CDK inhibitory activity)

RN 600639-31-4 CAPLUS


CN Benzenesulfonamide, N-(1,1-dimethylethyl)-4-[[4-[1-ethyl-2-(2-hydroxy-2-methylpropyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 600639-33-6 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2-(3-butenyl)-1-propyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)-N-[[2-(trimethylsilyl)ethoxy]methyl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

- SiMe<sub>3</sub>


RN 600639-38-1 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2-formyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)-N-[[2-(trimethylsilyl)ethoxy]methyl]-(9CI) (CA INDEX NAME)




RN 600639-39-2 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[[4-[1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-[[2-(trimethylsilyl)ethoxy]methyl]-(9CI) (CA INDEX NAME)




RN 600639-40-5 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 600639-41-6 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[[4-(2-methyl-1-propyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[2-(trimethylsilyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)



RN 600639-44-9 CAPLUS


CN Benzenesulfonamide, N-(1,1-dimethylethyl)-4-[[4-[1-ethyl-2-(2-methyl-1-propenyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 600639-50-7 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2-[2-(4-chlorophenyl)ethyl]-1-methyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



— OMe

RE.CNT 6      THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L8 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:737752 CAPLUS  
 DN 139:261315  
 TI Preparation of 4-imidazolyl 2-sulfamoylanilino substituted pyrimidines  
 with CDK inhibitory activity  
 IN Newcombe, Nicholas John; Thomas, Andrew Peter  
 PA Astrazeneca AB, Swed.; Astrazeneca UK Limited  
 SO PCT Int. Appl., 41 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2003076433	A1	20030918	WO 2003-GB904	20030306	
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	AU 2003208467	A1	20030922	AU 2003-208467	20030306	
	EP 1485374	A1	20041215	EP 2003-706755	20030306	
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK		
	US 2005119291	A1	20050602	US 2003-507163	20030306	
	JP 2005526764	T	20050908	JP 2003-574650	20030306	
PRAI	GB 2002-5690	A	20020309			
	WO 2003-GB904	W	20030306			

OS MARPAT.139:261315

AB The title compds. [I; R1 = halo, CN, alkyl, alkoxy; p = 0-2; R2 = H, alkyl, alkenyl, cycloalkyl, etc.; R3 = H, halo, CN; R4 = alkyl, alkoxyalkyl; R5 = (un)substituted alkyl, alkenyl; R6 = halo, alkyl; with proviso], useful as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man, were prepared and formulated. Thus, treating 2-anilino-4-(1,2-diethyl-4-methylimidazol-5-yl)pyrimidine (preparation given) with ClSO<sub>3</sub>H in SOCl<sub>2</sub> followed by reaction of the resulting intermediate 2-methoxyethylamine in iso-PrOH afforded 40% I [p = 0; R2 = (CH<sub>2</sub>)<sub>2</sub>OMe; R3 = H; R4, R5 = Et; R6 = Me]. In general, the compds. I demonstrated IC<sub>50</sub> values in the range 250 μM to 1 nM in the in vitro assay for testing CDK inhibitory activity.


IT 601479-36-1P 601479-37-2P 601479-38-3P  
 601479-39-4P 601479-40-7P 601479-41-8P  
 601479-42-9P 601479-43-0P 601479-44-1P  
 601479-45-2P 601479-46-3P 601479-47-4P  
 601479-48-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-imidazolyl 2-sulfamoylanilino substituted pyrimidines with CDK inhibitory activity)


RN 601479-36-1 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-diethyl-4-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 601479-37-2 CAPLUS

CN Benzenesulfonamide, N-(2-ethoxyethyl)-4-[[4-(1-ethyl-2,4-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 601479-38-3 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2,4-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 601479-39-4 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2,4-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 601479-40-7 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2,4-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)




RN 601479-41-8 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2,4-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 601479-42-9 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2,4-dimethyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 601479-43-0 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2,4-dimethyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 601479-44-1 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2,4-dimethyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 601479-45-2 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2,4-dimethyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)




RN 601479-46-3 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2,4-dimethyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)




RN 601479-47-4 CAPLUS

CN Benzenesulfonamide, N-[2-(1H-pyrazol-1-yl)ethyl]-4-[[4-(1,2,4-trimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 601479-48-5 CAPLUS

CN Benzenesulfonamide, 4-[[4-(4-bromo-1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




IT 403791-35-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 4-imidazolyl 2-sulfamoylanilino substituted pyrimidines with  
CDK inhibitory activity)

RN 403791-35-5 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-  
pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:376852 CAPLUS  
 DN 138:385443  
 TI Preparation of amino imidazolyl pyrimidinecarboxaldehyde  
 thiosemicarbazones, pyridine analogs and related compounds as inhibitors  
 of Ikb kinases  
 IN Hawley, Ronald Charles; Labadie, Sharada Shenvi; Sjogren, Eric Brian;  
 Talamas, Francisco Xavier  
 PA F. Hoffmann-La Roche AG, Switz.  
 SO PCT Int. Appl., 98 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003040131	A1	20030515	WO 2002-EP12164	20021031
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				
	PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,				
	UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,				
	CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,				
	PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,				
	NE, SN, TD, TG				
	CA 2465711	A1	20030515	CA 2002-2465711	20021031
	AU 2002350657	A1	20030519	AU 2002-350657	20021031
	EP 1444223	A1	20040811	EP 2002-785344	20021031
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002013899	A	20040831	BR 2002-13899	20021031
	CN 1582284	A	20050216	CN 2002-822194	20021031
	JP 2005511608	T	20050428	JP 2003-542177	20021031
	US 2003144303	A1	20030731	US 2002-288968	20021106
	US 6846828	B2	20050125		
	US 2005107403	A1	20050519	US 2004-967430	20041018
	US 7157580	B2	20070102		
PRAI	US 2001-338312P	P	20011107		
	WO 2002-EP12164	W	20021031		
	US 2002-288968	A3	20021106		

OS MARPAT 138:385443

AB The present invention relates to aminopyrimidine and aminopyridine derivs. (shown as I; variables defined below; e.g. 2-butylamino-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-methylthiosemicarbazone (1)) and methods for their preparation. The compds. are useful as inhibitors of Ikb kinases and, therefore, may be used for the treatment of inflammatory, metabolic or malignant conditions (e.g. rheumatoid arthritis, inflammatory bowel disease, psoriasis, cancer, diabetes and septic shock). IC50 values for inhibition of IKK $\beta$  enzyme activity are reported for 3 examples of I; e.g. 0.314  $\mu$ M for 1. Eleven example preps. of intermediates and I and characterization data for .apprx.150 I are included. For example, 2-isopropylamino-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-methylthiosemicarbazone was prepared in 7 steps starting from Et diethoxyacetate, thiourea and benzyl bromide giving 2-benzylsulfanyl-6-diethoxymethylpyrimidin-4-ol as the 1st intermediate (50%); this intermediate was sequentially converted to the chloride (74%), pyrimidine imidazole, sulfone (31% for 2 steps), amino pyrimidine acetal (66%), aldehyde (64%) and finally the aldehyde thiosemicarbazone (71%). For I:


one of either V or X is N and the other is CRa, or both V and X are CRa (Ra = H, (C1-C6)alkyl, (C3-C7)cycloalkyl or (C3-C7)cycloalkyl(C1-C6)alkyl); Y is O, S or NR (R is H, CN, NO<sub>2</sub>, (C1-C10)alkyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl-(C1-C6)alkyl, (C3-C10)alkenyl or (C2-C10)alkynyl). Z is H, (C1-C6)alkyl, (C3-C7)cycloalkyl, (C3-C6)cycloalkyl(C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl or N(R<sub>2</sub>)(R<sub>3</sub>); R<sub>1</sub> is H, (C1-C10)alkyl, (C3-C10)alkenyl, (C2-C10)alkynyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl(C1-C6)alkyl, (C1-C10)heteroalkyl, heterocyclyl, heterocyclyl (C1-C6)alkyl, aryl, aryl(C1-C4)alkyl, aryl(C1-C4) heteroalkyl, heteroaryl(C1-C4)alkyl, heteroaryl(C1-C4)heteroalkyl, C(O)R<sub>11</sub> or (C1-C6)alkylene-C(O)R<sub>11</sub>; R<sub>4</sub> is H, (C1-C6)alkyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl(C1-C6)alkyl, (C2-C6)alkenyl or (C2-C6)alkynyl; A is H, (C1-C10)alkyl, (C3-C10)alkenyl, (C2-C10)alkynyl, halo (C1-C6) alkyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl(C1-C6)alkyl, (C1-C10)heteroalkyl, heterocyclyl, heterocyclyl(C1-C6) alkyl, heterosubstituted (C3-C7)cycloalkyl, aryl, aryl(C1-C4)alkyl, aryl(C1-C4)heteroalkyl, heteroaryl, heteroaryl(C1-C4)alkyl, heteroaryl(C1-C4)heteroalkyl or RaRbNC(:X) (Ra and Rb = H, (C1-C4)alkyl or aryl). X is O or S; B is a (un)substituted five- or six-membered aromatic ring containing at least 1 N and 0-3 addnl. heteroatoms, wherein the B ring substituents = halogen, CF<sub>3</sub>, CF<sub>3</sub>O, (C1-C6)alkyl, amino, (C1-C6)alkylamino, di(C1-C6)alkylamino, cyano, nitro, sulfonamido, acyl, acylamino and carboxamido; U is -NR<sub>5</sub>-, -O- or -S-; addnl. details are given in the claims.

IT 525559-89-1P, 2-((4-(Methylsulfonyl)phenyl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-methylthiosemicarbazone  
525559-94-8P, 2-((3-(Methylsulfonyl)phenyl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-methylthiosemicarbazone  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of amino imidazolyl pyrimidinecarboxaldehyde thiosemicarbazones, pyrimidine analogs and related compds. as inhibitors of Ikb kinases)


RN 525559-89-1 CAPLUS

CN Hydrazinecarbothioamide, 1-methyl-2-[[6-(1-methyl-1H-imidazol-5-yl)-2-[[4-(methylsulfonyl)phenyl]amino]-4-pyrimidinyl]methylene]- (9CI) (CA INDEX NAME)



RN 525559-94-8 CAPLUS

CN Hydrazinecarbothioamide, 1-methyl-2-[[6-(1-methyl-1H-imidazol-5-yl)-2-[[3-(methylsulfonyl)phenyl]amino]-4-pyrimidinyl]methylene]- (9CI) (CA INDEX NAME)



RE.CNT 4      THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L8 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2002:185108 CAPLUS  
 DN 136:247599  
 TI Preparation of imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation  
 IN Breault, Gloria Anne; Newcombe, Nicholas John; Thomas, Andrew Peter  
 PA Astrazeneca AB, Swed.; Astrazeneca UK Limited  
 SO PCT Int. Appl., 108 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

*Common Inv.*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002020512	A1	20020314	WO 2001-GB3864	20010830
	WO 2002020512	A9	20040506		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2417148	A1	20020314	CA 2001-2417148	20010830
	AU 200184192	A	20020322	AU 2001-84192	20010830
	BR 2001013496	A	20030701	BR 2001-13496	20010830
	EP 1351958	A1	20031015	EP 2001-963159	20010830
	EP 1351958	B1	20040616		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	HU 200302922	A2	20031229	HU 2003-2922	20010830
	JP 2004508365	T	20040318	JP 2002-525133	20010830
	JP 3523641	B2	20040426		
	AT 269327	T	20040715	AT 2001-963159	20010830
	NZ 523787	A	20040924	NZ 2001-523787	20010830
	PT 1351958	T	20040930	PT 2001-963159	20010830
	ES 2221904	T3	20050116	ES 2001-1963159	20010830
	EE 200300088	A	20050215	EE 2003-88	20010830
	RU 2284327	C2	20060927	RU 2003-109612	20010830
	TW 242559	B	20051101	TW 2001-90122494	20010911
	ZA 2003000612	A	20040422	ZA 2003-612	20030122
	BG 107579	A	20031031	BG 2003-107579	20030221
	NO 2003001006	A	20030304	NO 2003-1006	20030304
	US 2004014776	A1	20040122	US 2003-363655	20030304
	US 6969714	B2	20051129		
	HK 1057553	A1	20041231	HK 2004-100403	20040119
	US 2006004033	A1	20060105	US 2005-169197	20050629
PRAI	GB 2000-21726	A	20000905		
	WO 2001-GB3864	W	20010830		
	US 2003-363655	A1	20030304		
OS	MARPAT 136:247599				
AB	Title compds. I [R1 = halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, alk(en/yn)yl, alkoxy; p = 0-4; R2 = sulfamoyl, Ra-Rb; q = 0-2; p + q = 0-5; R3 = halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, alk(en/yn)yl, alkoxy, alkanoyl, etc.; n = 0-2, R4 = H, alk(en/yn)yl, cycloalkyl, Ph, etc.; R5-6 = H, halo, nitro, cyano, hydroxy,				

trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, alk(en/yn)yl, alkoxy, etc.; Ra = alk(en/yn)yl, cycloalkyl, Ph, heterocyclyl, phenyl-alkyl, etc.; Rb = C(O), amido, carboxamido, etc.] were prepared For instance, phenylguanidine hydrogen carbonate was condensed with 5-(3-dimethylaminoprop-2-en-1-oyl)-1-methylimidazole (i-PrOH, NaOMe, reflux, 3 h) to give II in 64% yield. The CDK2 inhibitory activity of II was measured as IC<sub>50</sub> = 0.146  $\mu$ M.


IT 403791-04-8P, 4-(2-Methylimidazol-5-yl)-2-(4-sulfamoylanilino)pyrimidine 403791-36-6P, 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-t-butoxycarbonylsulfamoyl)anilino)pyrimidin

e  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug; imidazolo-5-yl-2-anilino-pyrimidines as agents for inhibition of cell proliferation)


RN 403791-04-8 CAPLUS

CN Benzenesulfonamide, 4-[[4-(2-methyl-1H-imidazol-4-yl)-2-pyrimidinyl]amino]-(9CI) (CA INDEX NAME)



RN 403791-36-6 CAPLUS

CN Carbamic acid, [[4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 403791-06-0P, 4-(1,2-Dimethylimidazol-5-yl)-2-(4-sulfamoylanilino)pyrimidine 403791-15-1P, 4-(1-Methylimidazol-5-yl)-2-(4-sulfamoylanilino)pyrimidine 403791-16-2P, 2-(4-(N-(3-Methoxypropyl)sulfamoyl)anilino)-4-(1-methylimidazol-5-yl)pyrimidine 403791-17-3P, 4-(1-Methylimidazol-5-yl)-2-(4-(N-propylsulfamoyl)anilino)pyrimidine 403791-18-4P, 2-(4-(N-(2,3-Dihydroxypropyl)sulfamoyl)anilino)-4-(1-methylimidazol-5-yl)pyrimidine 403791-19-5P, 2-(4-(N-(2-(2-Hydroxyethoxy)ethyl)sulfamoyl)anilino)-4-(1-methylimidazol-5-yl)pyrimidine 403791-20-8P, 2-(4-(N-(2-Furanylmethyl)sulfamoyl)anilino)-4-(1-methylimidazol-5-yl)pyrimidine 403791-21-9P, 2-(4-(N-(2-Hydroxyethyl)sulfamoyl)anilino)-4-(1-methylimidazol-5-yl)pyrimidine 403791-22-0P, 2-(4-(N-(Carbamoylmethyl)sulfamoyl)anilino)-4-(1-methylimidazol-5-yl)pyrimidine 403791-23-1P, 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(3-

methoxypropyl)sulfamoyl)anilino)pyrimidine 403791-24-2P,  
 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(4-fluorobenzyl)sulfamoyl)anilino)pyrimidine 403791-25-3P, 2-(4-(N-(Cyclopropylmethyl)sulfamoyl)anilino)-4-(1,2-dimethylimidazol-5-yl)pyrimidine 403791-26-4P  
 403791-27-5P, 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-((tetrahydrofuran-2-yl)methyl)sulfamoyl)anilino)pyrimidine 403791-35-5P, 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(2-methoxyethyl)sulfamoyl)anilino)pyrimidine 403791-37-7P,  
 4-(1-Ethyl-2-methylimidazol-5-yl)-2-(4-(N-(2-methoxyethyl)sulfamoyl)anilino)pyrimidine 403791-38-8P, 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)sulfamoyl)anilino)pyrimidine 403791-39-9P, 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(2-benzyloxyethyl)sulfamoyl)anilino)pyrimidine 403791-40-2P,  
 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(2,2-dimethoxyethyl)sulfamoyl)anilino)pyrimidine 403791-41-3P, 4-(1-Ethyl-2-methylimidazol-5-yl)-2-(4-(N-((tetrahydrofuran-2-yl)methyl)sulfamoyl)anilino)pyrimidine 403791-42-4P, 4-(1-Ethyl-2-methylimidazol-5-yl)-2-(4-(N-(3-methoxypropyl)sulfamoyl)anilino)pyrimidine 403791-43-5P,  
 4-(1-Ethyl-2-methylimidazol-5-yl)-2-(4-(N-(cyclopropylmethyl)sulfamoyl)anilino)pyrimidine 403791-44-6P, 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(2-methoxyethyl)-N-methylsulfamoyl)anilino)pyrimidine 403791-45-7P, 4-(1-Ethyl-2-methylimidazol-5-yl)-2-(4-(N-(2-methoxyethyl)-N-methylsulfamoyl)anilino)pyrimidine 403791-46-8P,  
 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(methanesulfonyl)anilino)pyrimidine 403791-47-9P, 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(3-morpholinopropyl)-N-methylsulfamoyl)anilino)pyrimidine 403791-48-0P, 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(3-(N,N-dimethylamino)propylsulfonyl)anilino)pyrimidine 403791-49-1P,  
 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(3,3,3-trifluoropropylsulfonyl)anilino)pyrimidine 403791-50-4P, 4-(1,2-Dimethylimidazol-5-yl)-2-(4-butylsulfonylanilino)pyrimidine 403791-51-5P,  
 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(3-methoxypropylsulfonyl)anilino)pyrimidine 403791-52-6P, 4-(1-Ethyl-2-methylimidazol-5-yl)-2-(4-(N-(2-(methoxymethoxy)ethyl)sulfamoyl)anilino)pyrimidine 403791-53-7P,  
 4-(1-Ethyl-2-methylimidazol-5-yl)-2-(4-(N-cyclopropylsulfamoyl)anilino)pyrimidine 403791-54-8P, 4-(1-Ethyl-2-methylimidazol-5-yl)-2-(4-(N-(4-methylthiazol-2-ylmethyl)sulfamoyl)anilino)pyrimidine 403791-55-9P, 4-(1-Ethyl-2-methylimidazol-5-yl)-2-(4-(N-(3-methylisoxazol-5-ylmethyl)sulfamoyl)anilino)pyrimidine 403791-56-0P, 4-(1-Ethyl-2-methylimidazol-5-yl)-2-(4-(N-(1,4-dioxan-2-yl)methylsulfamoyl)anilino)pyrimidine 403791-57-1P,  
 5-Chloro-4-(1,2-dimethylimidazol-5-yl)-2-(4-(N-propylsulfamoyl)anilino)pyrimidine 403791-58-2P, 5-Chloro-4-(1,2-dimethylimidazol-5-yl)-2-(4-(N-(cyclopropylmethyl)sulfamoyl)anilino)pyrimidine 403791-59-3P,  
 5-Chloro-4-(1,2-dimethylimidazol-5-yl)-2-(4-(N-(3-methoxypropyl)sulfamoyl)anilino)pyrimidine 403791-60-6P, 5-Chloro-4-(1,2-dimethylimidazol-5-yl)-2-(4-(N-(tert-butyl)sulfamoyl)anilino)pyrimidine 403791-61-7P,  
 4-(1-(2-Methoxyethyl)-2-methylimidazol-5-yl)-2-(4-(N-(2-methoxyethyl)sulfamoyl)anilino)pyrimidine 403791-62-8P, 4-(1-(1-Butene-4-yl)-2-methylimidazol-5-yl)-2-(4-(N-(2-methoxyethyl)sulfamoyl)anilino)pyrimidine 403791-64-0P,  
 4-(1-Methyl-2-ethylimidazol-5-yl)-2-(4-(N-(tetrahydrofuran-2-ylmethyl)sulfamoyl)anilino)pyrimidine 403791-65-1P, 4-(1-Methyl-2-ethylimidazol-5-yl)-2-(4-(N-(2-methoxyethyl)sulfamoyl)anilino)pyrimidine 403791-66-2P, 4-(1-Methyl-2-isopropylimidazol-5-yl)-2-(4-(N-(2-methoxyethyl)sulfamoyl)anilino)pyrimidine 403791-67-3P,  
 4-(1-Methyl-2-isopropylimidazol-5-yl)-2-(4-(N-(cyclopropylmethyl)sulfamoyl)anilino)pyrimidine 403791-68-4P,

4-(1-Methyl-2-isopropylimidazol-5-yl)-2-(4-(N-(tetrahydrofuran-2-ylmethyl)sulfamoyl)anilino)pyrimidine 403791-69-5P,  
 4-(1-Methyl-2-ethylimidazol-5-yl)-2-(4-(N-(cyclopropylmethyl)sulfamoyl)anilino)pyrimidine 403791-71-9P, 5-Chloro-4-(1,2-dimethylimidazol-5-yl)-2-(4-(N-tert-butyl-N-methylsulfamoyl)anilino)pyrimidine 403791-72-0P, 4-(1-Ethyl-2-methylimidazol-5-yl)-2-(4-(N-allylsulfamoyl)anilino)pyrimidine 403791-73-1P,  
 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(2-(2-methoxyethoxy)ethyl)sulfamoyl)anilino)pyrimidine hydrochloride 403791-74-2P,  
 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(2-(2-(2-methoxyethoxy)ethoxy)ethyl)sulfamoyl)anilino)pyrimidine 403791-75-3P, 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethyl)sulfamoyl)anilino)pyrimidine hydrochloride 403791-76-4P, 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(2-(methanesulfonyl)ethyl)sulfamoyl)anilino)pyrimidine 403791-77-5P, 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(3-morpholinopropyl)sulfamoyl)anilino)pyrimidine 403791-78-6P,  
 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(2-(N,N-dimethylamino)ethyl)sulfamoyl)anilino)pyrimidine 403791-79-7P,  
 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(2-(piperidin-1-yl)ethyl)sulfamoyl)anilino)pyrimidine 403791-80-0P,  
 4-(1-(2-Methoxyethyl)-2-methylimidazol-5-yl)-2-(4-(N-((tetrahydrofuran-2-yl)methyl)sulfamoyl)anilino)pyrimidine 403791-81-1P,  
 4-(1-(2-Methoxyethyl)-2-methylimidazol-5-yl)-2-(4-(N-(cyclopropylmethyl)sulfamoyl)anilino)pyrimidine 403791-82-2P,  
 4-(1-(2-Methoxyethyl)-2-methylimidazol-5-yl)-2-(4-(N-(3-methoxypropyl)sulfamoyl)anilino)pyrimidine 403791-83-3P,  
 4-(1-Ethyl-2-methylimidazol-5-yl)-2-(4-(N-(hydroxyethyl)sulfamoyl)anilino)pyrimidine 403791-84-4P, 4-(1-Ethyl-2-methylimidazol-5-yl)-2-(4-(N-(3-hydroxy-2,2-dimethyl-propyl)sulfamoyl)anilino)pyrimidine 403791-85-5P, 4-(1-Ethyl-2-methylimidazol-5-yl)-2-(4-(N-(3-hydroxypropyl)sulfamoyl)anilino)pyrimidine 403791-86-6P,  
 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-allylsulfamoyl)anilino)pyrimidine 403791-87-7P, 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(1-propyn-3-yl)sulfamoyl)anilino)pyrimidine 403791-88-8P,  
 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(2,2-dimethyl-3-hydroxypropyl)sulfamoyl)anilino)pyrimidine 403791-89-9P,  
 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(3-hydroxypropyl)sulfamoyl)anilino)pyrimidine 403791-90-2P, 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-ethylsulfamoyl)anilino)pyrimidine 403791-91-3P,  
 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(2-hydroxyethyl)sulfamoyl)anilino)pyrimidine 403791-92-4P, 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(2-(2-hydroxyethoxy)ethyl)sulfamoyl)anilino)pyrimidine 403791-93-5P,  
 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-((pyridin-2-yl)methyl)sulfamoyl)anilino)pyrimidine 403791-94-6P,  
 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-((pyridin-3-yl)methyl)sulfamoyl)anilino)pyrimidine 403791-95-7P,  
 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(pentylsulfamoyl)anilino)pyrimidine 403791-96-8P, 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(5-hydroxypentyl)sulfamoyl)anilino)pyrimidine 403791-97-9P,  
 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(3-ethoxypropyl)sulfamoyl)anilino)pyrimidine 403791-98-0P, 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(2-hydroxypropyl)sulfamoyl)anilino)pyrimidine 403791-99-1P,  
 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(3-isopropoxypropyl)sulfamoyl)anilino)pyrimidine 403792-00-7P, 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(2-hydroxybutyl)sulfamoyl)anilino)pyrimidine 403792-01-8P,  
 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(2-(pyridin-2-yl)ethyl)sulfamoyl)anilino)pyrimidine 403792-02-9P,  
 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(2-(pyridin-4-yl)ethyl)sulfamoyl)anilino)pyrimidine 403792-03-0P,


4-(1-Methyl-2-ethylimidazol-5-yl)-2-(4-(N-cyclopropylsulfamoyl)anilino)pyrimidine 403792-04-1P, 4-(1-(2,2,2-Trifluoroethyl)-2-methylimidazol-5-yl)-2-(4-(N-(cyclopropylmethyl)sulfamoyl)anilino)pyrimidine 403792-05-2P, 4-(1-(2,2,2-Trifluoroethyl)-2-methylimidazol-5-yl)-2-(4-(N-(2-methoxyethyl)sulfamoyl)anilino)pyrimidine 403792-06-3P, 4-(1-(2,2,2-Trifluoroethyl)-2-methylimidazol-5-yl)-2-(4-(N-cyclopropylsulfamoyl)anilino)pyrimidine 403792-07-4P, 4-(1-Isopropyl-2-methylimidazol-5-yl)-2-(4-(N-(2-methoxyethyl)sulfamoyl)anilino)pyrimidine 403792-08-5P, 4-(1,2,4-Trimethylimidazol-5-yl)-2-(4-(N-(2-methoxyethyl)sulfamoyl)anilino)pyrimidine 403792-09-6P, 5-Bromo-4-(1,2-dimethylimidazol-5-yl)-2-(4-sulfamoylanilino)pyrimidine 403792-10-9P, 5-Bromo-4-(1,2-dimethylimidazol-5-yl)-2-(4-(N-propylsulfamoyl)anilino)pyrimidine 403792-11-0P, 5-Bromo-4-(1,2-dimethylimidazol-5-yl)-2-(4-(N-(3-methoxypropyl)sulfamoyl)anilino)pyrimidine 403792-12-1P, 5-Bromo-4-(1,2-dimethylimidazol-5-yl)-2-(4-(N-methylsulfamoyl)anilino)pyrimidine 403792-13-2P, 5-Bromo-4-(1,2-dimethylimidazol-5-yl)-2-(4-(N-(cyclopropylmethyl)sulfamoyl)anilino)pyrimidine 403792-14-3P, 4-(1,2,4-Trimethylimidazol-5-yl)-2-(4-sulfamoylanilino)pyrimidine 403792-15-4P, 4-(1,2,4-Trimethylimidazol-5-yl)-2-(4-(N-methylsulfamoyl)anilino)pyrimidine 403792-16-5P, 4-(1,2,4-Trimethylimidazol-5-yl)-2-(4-(N-(3-(N,N-dimethylamino)propyl)sulfamoyl)anilino)pyrimidine 403792-17-6P, 4-(1,2,4-Trimethylimidazol-5-yl)-2-(4-(N-t-butylsulfamoyl)anilino)pyrimidine 403792-18-7P, 4-(1,2,4-Trimethylimidazol-5-yl)-2-(4-(N-(1,1-dimethylpropyl)sulfamoyl)anilino)pyrimidine 403792-19-8P, 4-(1,2,4-Trimethylimidazol-5-yl)-2-(4-(N-cyclopropylsulfamoyl)anilino)pyrimidine 403792-20-1P, 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-propylsulfamoyl)anilino)pyrimidine 403792-21-2P, 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-cyclopropylsulfamoyl)anilino)pyrimidine 403792-22-3P, 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-cyclobutylsulfamoyl)anilino)pyrimidine 403792-23-4P, 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(2,2,2-trifluoroethyl)sulfamoyl)anilino)pyrimidine 403792-24-5P, 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(3-trifluoromethylphenyl)sulfamoyl)anilino)pyrimidine 403792-25-6P, 4-(1-Ethyl-2-methylimidazol-5-yl)-2-(4-(N-methylsulfamoyl)anilino)pyrimidine 403792-26-7P, 4-(1-Ethyl-2-methylimidazol-5-yl)-2-(4-(N-(2-(2-(hydroxy)ethoxy)ethyl)sulfamoyl)anilino)pyrimidine 403792-27-8P, 4-(1-Ethyl-2-methylimidazol-5-yl)-2-(4-(N-(3-isopropoxy-2-hydroxypropyl)sulfamoyl)anilino)pyrimidine 403792-28-9P, 4-(1-Ethyl-2-methylimidazol-5-yl)-2-(4-(N-(2-((isoxazol-3-yl)oxy)ethyl)sulfamoyl)anilino)pyrimidine 403792-29-0P, 4-(1-Ethyl-2-methylimidazol-5-yl)-2-(4-(N-(2-((isothiazol-3-yl)oxy)ethyl)sulfamoyl)anilino)pyrimidine 403792-30-3P, 4-(1-Ethyl-2-methylimidazol-5-yl)-2-(4-(N-(2-(1,2,5-thiadiazol-3-yl)oxy)ethyl)sulfamoyl)anilino)pyrimidine 403792-31-4P, 4-(1-Ethyl-2-methylimidazol-5-yl)-2-(4-(N-(3-((isoxazol-3-yl)oxy)propyl)sulfamoyl)anilino)pyrimidine 403792-32-5P, 4-(1-Ethyl-2-methylimidazol-5-yl)-2-(4-(N-(3-((isothiazol-3-yl)oxy)propyl)sulfamoyl)anilino)pyrimidine 403792-33-6P, 4-(1-Ethyl-2-methylimidazol-5-yl)-2-(4-(N-(3-(1,2,5-thiadiazol-3-yl)oxy)propyl)sulfamoyl)anilino)pyrimidine 403792-34-7P, 4-(1-Methyl-2-ethylimidazol-5-yl)-2-(4-(N-cyclobutylsulfamoyl)anilino)pyrimidine 403792-35-8P, 4-(1-(2,2,2-Trifluoroethyl)-2-methylimidazol-5-yl)-2-(4-(N-cyclobutylsulfamoyl)anilino)pyrimidine 403792-36-9P, 4-(1-Isopropyl-2-methylimidazol-5-yl)-2-(4-(N-cyclobutylsulfamoyl)anilino)pyrimidine 403792-37-0P,

4-(1-Isopropyl-2-methylimidazol-5-yl)-2-(4-(N-cyclopropylsulfamoyl)anilino)pyrimidine 403792-38-1P,  
 4-(1-Isopropyl-2-methylimidazol-5-yl)-2-(4-(N-(cyclopropylmethyl)sulfamoyl)anilino)pyrimidine 403792-39-2P,  
 4-(1-Isopropyl-2-methylimidazol-5-yl)-2-(4-(N-(cyanomethyl)sulfamoyl)anilino)pyrimidine 403792-40-5P,  
 4-(1-Isopropyl-2-methylimidazol-5-yl)-2-(4-(N-((pyridin-2-yl)methyl)sulfamoyl)anilino)pyrimidine 403792-41-6P,  
 4-(1-Ethyl-2-methylimidazol-5-yl)-2-(4-(N-(5-methylpyrazin-2-ylmethyl)sulfamoyl)anilino)pyrimidine 403792-42-7P,  
 4-(1-Methyl-2-methoxymethylimidazol-5-yl)-2-(4-(N-(2-methoxyethyl)sulfamoyl)anilino)pyrimidine 403792-43-8P,  
 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(3-((isothiazol-3-yl)oxy)propyl)sulfamoyl)anilino)pyrimidine 403792-44-9P,  
 4-(1-Ethyl-2-methylimidazol-5-yl)-2-(4-(N-(2-propynyl)sulfamoyl)anilino)pyrimidine 403792-45-0P, 5-Bromo-4-(1,2-dimethylimidazol-5-yl)-2-(4-(N-(2-methoxyethyl)sulfamoyl)anilino)pyrimidine 403792-46-1P,  
 5-Bromo-4-(1-ethyl-2-methylimidazol-5-yl)-2-(4-(N-(2-methoxyethyl)sulfamoyl)anilino)pyrimidine 403792-47-2P,  
 5-Bromo-4-(1-(2-methoxyethyl)-2-methylimidazol-5-yl)-2-(4-(N-(2-methoxyethyl)sulfamoyl)anilino)pyrimidine 403792-48-3P,  
 5-Bromo-4-(1-(2-methoxyethyl)-2-methylimidazol-5-yl)-2-(4-(N-(3-methoxypropyl)sulfamoyl)anilino)pyrimidine 403792-49-4P,  
 5-Chloro-4-(1-ethyl-2-methylimidazol-5-yl)-2-(4-(N-(2-methoxyethyl)sulfamoyl)anilino)pyrimidine 403792-50-7P,  
 5-Chloro-4-(1,2-dimethylimidazol-5-yl)-2-(4-(N-(2-methoxyethyl)sulfamoyl)anilino)pyrimidine 403792-51-8P,  
 5-Chloro-4-(1-ethyl-2-methylimidazol-5-yl)-2-(4-(N-(tetrahydrofuran-2-ylmethyl)sulfamoyl)anilino)pyrimidine 403792-52-9P,  
 5-Chloro-4-(1-ethyl-2-methylimidazol-5-yl)-2-(4-(N-cyclopropylsulfamoyl)anilino)pyrimidine 403792-53-0P,  
 5-Chloro-4-(1-(2-methoxyethyl)-2-methylimidazol-5-yl)-2-(4-(N-(2-methoxyethyl)sulfamoyl)anilino)pyrimidine 403792-55-2P,  
 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(2,3-dihydroxypropyl)sulfamoyl)anilino)pyrimidine 403792-57-4P, 5-Chloro-4-(1,2-dimethylimidazol-5-yl)-2-(4-sulfamoylanilino)pyrimidine 403792-59-6P,  
 5-Chloro-4-(1,2-dimethylimidazol-5-yl)-2-(4-(N-methylsulfamoyl)anilino)pyrimidine 403792-61-0P,  
 5-Bromo-4-(1-methylimidazol-5-yl)-2-(4-sulfamoylanilino)pyrimidine 403792-64-3P, 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-methylsulfamoyl)anilino)pyrimidine 403792-65-4P,  
 4-(1,2-Dimethylimidazol-5-yl)-2-(2-methoxy-4-(N-methylsulfamoyl)-5-methylanilino)pyrimidine 403792-66-5P, 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(4,5-dimethyloxazol-2-yl)sulfamoyl)anilino)pyrimidine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug; imidazolo-5-yl-2-anilino-pyrimidines as agents for inhibition of cell proliferation)


RN 403791-06-0 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403791-15-1 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-  
(9CI) (CA INDEX NAME)




RN 403791-16-2 CAPLUS

CN Benzenesulfonamide, N-(3-methoxypropyl)-4-[[4-(1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403791-17-3 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-  
N-propyl- (9CI) (CA INDEX NAME)




RN 403791-18-4 CAPLUS

CN Benzenesulfonamide, N-(2,3-dihydroxypropyl)-4-[[4-(1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403791-19-5 CAPLUS

CN Benzenesulfonamide, N-[2-(2-hydroxyethoxy)ethyl]-4-[[4-(1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403791-20-8 CAPLUS

CN Benzenesulfonamide, N-(2-furanylmethyl)-4-[[4-(1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 403791-21-9 CAPLUS


CN Benzenesulfonamide, N-(2-hydroxyethyl)-4-[[4-(1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 403791-22-0 CAPLUS


CN Acetamide, 2-[[[4-[[4-(1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)






RN 403791-23-1 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 403791-24-2 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 403791-25-3 CAPLUS

CN Benzenesulfonamide, N-(cyclopropylmethyl)-4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403791-26-4 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 403791-27-5 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 403791-35-5 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 403791-37-7 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 403791-38-8 CAPLUS

CN Benzenesulfonamide, N-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403791-39-9 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[2-(phenylmethoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 403791-40-2 CAPLUS

CN Benzenesulfonamide, N-(2,2-dimethoxyethyl)-4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403791-41-3 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[(2,2-dimethoxyethyl)methyl]- (9CI) (CA INDEX NAME)




RN 403791-42-4 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 403791-43-5 CAPLUS

CN Benzenesulfonamide, N-(cyclopropylmethyl)-4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403791-44-6 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 403791-45-7 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 403791-46-8 CAPLUS

CN 2-Pyrimidinamine, 4-(1,2-dimethyl-1H-imidazol-5-yl)-N-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 403791-47-9 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-methyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




RN 403791-48-0 CAPLUS

CN 2-Pyrimidinamine, N-[4-[[3-(dimethylamino)propyl]sulfonyl]phenyl]-4-(1,2-dimethyl-1H-imidazol-5-yl)- (9CI) (CA INDEX NAME)




RN 403791-49-1 CAPLUS

CN 2-Pyrimidinamine, 4-(1,2-dimethyl-1H-imidazol-5-yl)-N-[4-[(3,3,3-trifluoropropyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 403791-50-4 CAPLUS

CN 2-Pyrimidinamine, N-[4-(butylsulfonyl)phenyl]-4-(1,2-dimethyl-1H-imidazol-5-yl)- (9CI) (CA INDEX NAME)




RN 403791-51-5 CAPLUS

CN 2-Pyrimidinamine, 4-(1,2-dimethyl-1H-imidazol-5-yl)-N-[4-[(3-methoxypropyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 403791-52-6 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[2-(methoxymethoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 403791-53-7 CAPLUS

CN Benzenesulfonamide, N-cyclopropyl-4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403791-54-8 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[(4-methyl-2-thiazolyl)methyl]- (9CI) (CA INDEX NAME)




RN 403791-55-9 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[(3-methyl-5-isoxazolyl)methyl]- (9CI) (CA INDEX NAME)




RN 403791-56-0 CAPLUS

CN Benzenesulfonamide, N-(1,4-dioxan-2-ylmethyl)-4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403791-57-1 CAPLUS

CN Benzenesulfonamide, 4-[[5-chloro-4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-propyl- (9CI) (CA INDEX NAME)




RN 403791-58-2 CAPLUS

CN Benzenesulfonamide, 4-[[5-chloro-4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)




RN 403791-59-3 CAPLUS

CN Benzenesulfonamide, 4-[[5-chloro-4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 403791-60-6 CAPLUS

CN Benzenesulfonamide, 4-[[5-chloro-4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 403791-61-7 CAPLUS


CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[[4-[1-(2-methoxyethyl)-2-methyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 403791-62-8 CAPLUS


CN Benzenesulfonamide, 4-[[4-[1-(3-butenyl)-2-methyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)






RN 403791-64-0 CAPLUS

CN Benzenesulfonamide, 4-[[4-(2-ethyl-1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 403791-65-1 CAPLUS

CN Benzenesulfonamide, 4-[[4-(2-ethyl-1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 403791-66-2 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[[4-[1-methyl-2-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403791-67-3 CAPLUS

CN Benzenesulfonamide, N-(cyclopropylmethyl)-4-[[4-[1-methyl-2-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403791-68-4 CAPLUS

CN Benzenesulfonamide, 4-[[4-[1-methyl-2-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 403791-69-5 CAPLUS

CN Benzenesulfonamide, N-(cyclopropylmethyl)-4-[[4-(2-ethyl-1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403791-71-9 CAPLUS

CN Benzenesulfonamide, 4-[[5-chloro-4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 403791-72-0 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 403791-73-1 CAPLUS  
 CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[2-(2-methoxyethoxy)ethyl]-, monohydrochloride (9CI)  
 (CA INDEX NAME)



● HCl

RN 403791-74-2 CAPLUS  
 CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[2-[2-(2-methoxyethoxy)ethoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CH<sub>2</sub>—OMe


RN 403791-75-3 CAPLUS  
 CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-3,6,9,12-tetraoxatridec-1-yl-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




● HCl

PAGE 1-B




RN 403791-76-4 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[2-(methylsulfonyl)ethyl]- (9CI) (CA INDEX NAME)




RN 403791-77-5 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




RN 403791-78-6 CAPLUS

CN Benzenesulfonamide, N-[2-(dimethylamino)ethyl]-4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403791-79-7 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 403791-80-0 CAPLUS

CN Benzenesulfonamide, 4-[[4-[1-(2-methoxyethyl)-2-methyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 403791-81-1 CAPLUS

CN Benzenesulfonamide, N-(cyclopropylmethyl)-4-[[4-[1-(2-methoxyethyl)-2-methyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403791-82-2 CAPLUS

CN Benzenesulfonamide, 4-[[4-[1-(2-methoxyethyl)-2-methyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 403791-83-3 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 403791-84-4 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(3-hydroxy-2,2-dimethylpropyl)- (9CI) (CA INDEX NAME)




RN 403791-85-5 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(3-hydroxypropyl)- (9CI) (CA INDEX NAME)




RN 403791-86-6 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 403791-87-7 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-2-propynyl- (9CI) (CA INDEX NAME)




RN 403791-88-8 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(3-hydroxy-2,2-dimethylpropyl)- (9CI) (CA INDEX NAME)




RN 403791-89-9 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(3-hydroxypropyl)- (9CI) (CA INDEX NAME)




RN 403791-90-2 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-ethyl- (9CI) (CA INDEX NAME)




RN 403791-91-3 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 403791-92-4 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[2-(2-hydroxyethoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 403791-93-5 CAPLUS


CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 403791-94-6 CAPLUS


CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)






RN 403791-95-7 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-pentyl- (9CI) (CA INDEX NAME)




RN 403791-96-8 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(5-hydroxypentyl)- (9CI) (CA INDEX NAME)




RN 403791-97-9 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(3-ethoxypropyl)- (9CI) (CA INDEX NAME)




RN 403791-98-0 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-hydroxypropyl)- (9CI) (CA INDEX NAME)




RN 403791-99-1 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[3-(1-methylethoxy)propyl]- (9CI) (CA INDEX NAME)




RN 403792-00-7 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-hydroxybutyl)- (9CI) (CA INDEX NAME)




RN 403792-01-8 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 403792-02-9 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 403792-03-0 CAPLUS

CN Benzenesulfonamide, N-cyclopropyl-4-[[4-(2-ethyl-1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403792-04-1 CAPLUS

CN Benzenesulfonamide, N-(cyclopropylmethyl)-4-[[4-[2-methyl-1-(2,2,2-trifluoroethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403792-05-2 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[[4-[2-methyl-1-(2,2,2-trifluoroethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403792-06-3 CAPLUS

CN Benzenesulfonamide, N-cyclopropyl-4-[[4-[2-methyl-1-(2,2,2-trifluoroethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403792-07-4 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403792-08-5 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[[4-(1,2,4-trimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403792-09-6 CAPLUS

CN Benzenesulfonamide, 4-[[5-bromo-4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403792-10-9 CAPLUS

CN Benzenesulfonamide; 4-[[5-bromo-4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-propyl- (9CI) (CA INDEX NAME)




RN 403792-11-0 CAPLUS

CN Benzenesulfonamide, 4-[[5-bromo-4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 403792-12-1 CAPLUS

CN Benzenesulfonamide, 4-[[5-bromo-4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)




RN 403792-13-2 CAPLUS

CN Benzenesulfonamide, 4-[[5-bromo-4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)




RN 403792-14-3 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2,4-trimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403792-15-4 CAPLUS

CN Benzenesulfonamide, N-methyl-4-[[4-(1,2,4-trimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403792-16-5 CAPLUS

CN Benzenesulfonamide, N-[3-(dimethylamino)propyl]-4-[[4-(1,2,4-trimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 403792-17-6 CAPLUS


CN Benzenesulfonamide, N-(1,1-dimethylethyl)-4-[[4-(1,2,4-trimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 403792-18-7 CAPLUS


10/507,081

CN Benzenesulfonamide, N-(1,1-dimethylpropyl)-4-[[4-(1,2,4-trimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403792-19-8 CAPLUS

CN Benzenesulfonamide, N-cyclopropyl-4-[[4-(1,2,4-trimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403792-20-1 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-propyl- (9CI) (CA INDEX NAME)




RN 403792-21-2 CAPLUS

CN Benzenesulfonamide, N-cyclopropyl-4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403792-22-3 CAPLUS

CN Benzenesulfonamide, N-cyclobutyl-4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403792-23-4 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 403792-24-5 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 403792-25-6 CAPLUS


CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)



RN 403792-26-7 CAPLUS


CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[2-(2-hydroxyethoxy)ethyl]- (9CI) (CA INDEX NAME)






RN 403792-27-8 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[2-hydroxy-3-(1-methylethoxy)propyl]- (9CI) (CA INDEX NAME)




RN 403792-28-9 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[2-(3-isoxazolyloxy)ethyl]- (9CI) (CA INDEX NAME)




RN 403792-29-0 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[2-(3-isothiazolyloxy)ethyl]- (9CI) (CA INDEX NAME)




RN 403792-30-3 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[2-(1,2,5-thiadiazol-3-yloxy)ethyl]- (9CI) (CA INDEX NAME)




RN 403792-31-4 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[3-(3-isoxazolyloxy)propyl]- (9CI) (CA INDEX NAME)




RN 403792-32-5 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[3-(3-isothiazolyloxy)propyl]- (9CI) (CA INDEX NAME)




RN 403792-33-6 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[3-(1,2,5-thiadiazol-3-yloxy)propyl]- (9CI) (CA INDEX NAME)




RN 403792-34-7 CAPLUS

CN Benzenesulfonamide, N-cyclobutyl-4-[[4-(2-ethyl-1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403792-35-8 CAPLUS

CN Benzenesulfonamide, N-cyclobutyl-4-[[4-[2-methyl-1-(2,2,2-trifluoroethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403792-36-9 CAPLUS

CN Benzenesulfonamide, N-cyclobutyl-4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403792-37-0 CAPLUS

CN Benzenesulfonamide, N-cyclobutyl-4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403792-38-1 CAPLUS

CN Benzenesulfonamide, N-(cyclopropylmethyl)-4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403792-39-2 CAPLUS

CN Benzenesulfonamide, N-(cyanomethyl)-4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403792-40-5 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 403792-41-6 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[(5-methylpyrazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 403792-42-7 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[[4-[2-(methoxymethyl)-1-methyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403792-43-8 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[3-(3-isothiazolyloxy)propyl]- (9CI) (CA INDEX NAME)




RN 403792-44-9 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-2-propynyl- (9CI) (CA INDEX NAME)




RN 403792-45-0 CAPLUS

CN Benzenesulfonamide, 4-[[5-bromo-4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 403792-46-1 CAPLUS

CN Benzenesulfonamide, 4-[[5-bromo-4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 403792-47-2 CAPLUS

CN Benzenesulfonamide, 4-[[5-bromo-4-[1-(2-methoxyethyl)-2-methyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 403792-48-3 CAPLUS

CN Benzenesulfonamide, 4-[[5-bromo-4-[1-(2-methoxyethyl)-2-methyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 403792-49-4 CAPLUS

CN Benzenesulfonamide, 4-[[5-chloro-4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 403792-50-7 CAPLUS

CN Benzenesulfonamide, 4-[[5-chloro-4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 403792-51-8 CAPLUS

CN Benzenesulfonamide, 4-[[5-chloro-4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 403792-52-9 CAPLUS

CN Benzenesulfonamide, 4-[[5-chloro-4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-cyclopropyl- (9CI) (CA INDEX NAME)




RN 403792-53-0 CAPLUS

CN Benzenesulfonamide, 4-[[5-chloro-4-[1-(2-methoxyethyl)-2-methyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 403792-55-2 CAPLUS

CN Benzenesulfonamide, N-(2,3-dihydroxypropyl)-4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403792-57-4 CAPLUS

CN Benzenesulfonamide, 4-[[5-chloro-4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 403792-59-6 CAPLUS

CN Benzenesulfonamide, 4-[[5-chloro-4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)




RN 403792-61-0 CAPLUS

CN Benzenesulfonamide, 4-[[5-bromo-4-(1-methyl-1H-imidazol-5-yl)-2-




pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 403792-64-3 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)




RN 403792-65-4 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-5-methoxy-N,2-dimethyl- (9CI) (CA INDEX NAME)



RN 403792-66-5 CAPLUS

CN Benzenesulfonamide, 4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-(4,5-dimethyl-2-oxazolyl)- (9CI) (CA INDEX NAME)



IT 403792-78-9P, 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(tert-butoxycarbonyl)-N-(2-(2-methoxyethoxy)ethyl)sulfamoyl)anilino)pyrimidine  
 403793-17-9P, 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-(tert-butoxycarbonyl)-N-(2-(2-(2-methoxyethoxy)ethoxy)ethyl)sulfamoyl)anilino)pyrimidine  
 403793-18-0P, 4-(1,2-Dimethylimidazol-5-yl)-2-(4-(N-


(tert-butoxycarbonyl)-N-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethyl)sulfamoyl)anilino)pyrimidine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; imidazolo-5-yl-2-anilino-pyrimidines as agents for inhibition of cell proliferation)


RN 403792-78-9 CAPLUS

CN Carbamic acid, [[4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]sulfonyl][2-(2-methoxyethoxy)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 403793-17-9 CAPLUS

CN 2,5,8-Trioxa-11-azadodecan-12-oic acid, 11-[[4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



PAGE 1-A


PAGE 1-B

—CH<sub>2</sub>—OMe


RN 403793-18-0 CAPLUS

CN 2,5,8,11-Tetraoxa-14-azapentadecan-15-oic acid, 14-[[4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RE.CNT 2      THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/507,081

=> => d his

(FILE 'HOME' ENTERED AT 12:22:01 ON 02 MAY 2007)

FILE 'REGISTRY' ENTERED AT 12:22:18 ON 02 MAY 2007

L1           STRUCTURE UPLOADED  
L2           29 S L1 SSS SAM  
L3           485 S L1 SSS FUL  
L4           STRUCTURE UPLOADED  
L5           9 S L4 SSS SAM SUB=L3  
L6           97 S L4 SSS FUL SUB=L3  
L7           388 S L3 NOT L6

FILE 'CAPLUS' ENTERED AT 12:34:23 ON 02 MAY 2007

L8           9 S L7

FILE 'CAOLD' ENTERED AT 12:35:48 ON 02 MAY 2007

=> s 17

L9           0 L7

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.45	270.33

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-7.02

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 12:36:02 ON 02 MAY 2007